

# Adi Diab

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2467818/publications.pdf>

Version: 2024-02-01

94  
papers

11,283  
citations

87888

38  
h-index

64796

79  
g-index

100  
all docs

100  
docs citations

100  
times ranked

15439  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 71-83.	7.0	37
2	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. <i>Cancer</i> , 2022, 128, 975-983.	4.1	12
3	PIVOT-12: a phase III study of adjuvant bempedalesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	2.4	7
4	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. <i>Cancers</i> , 2022, 14, 1760.	3.7	20
5	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
6	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
7	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
8	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
9	Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. <i>European Urology</i> , 2022, 82, 365-373.	1.9	6
10	Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12147-TPS12147.	1.6	0
11	Radiologic features of immune checkpoint inhibitor-related nephritis with clinical correlation in biopsy-proven cases.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14585-e14585.	1.6	1
12	Tocilizumab in combination with ipilimumab and nivolumab in solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9600-TPS9600.	1.6	5
13	Melanoma of the External Auditory Canal: A Review of Seven Cases at a Tertiary Care Referral Center. <i>Laryngoscope</i> , 2021, 131, 165-172.	2.0	9
14	Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2021, 113, 532-542.	6.3	25
15	Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607.	1.6	156
16	Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. <i>Oncimmunology</i> , 2021, 10, 1927313.	4.6	27
17	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
18	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	9.4	32

#	ARTICLE	IF	CITATIONS
19	The efficacy of anti- $\epsilon$ programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	2.8	15
20	Cytokines in the Treatment of Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 83.	4.0	17
21	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
22	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
23	Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. <i>Endocrine-Related Cancer</i> , 2021, 28, 419-431.	3.1	29
24	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288.	7.0	21
25	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205.	5.2	95
26	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	1.6	55
27	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67.	0.6	45
28	Current strategies for intratumoural immunotherapy “ Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 157, 493-510.	2.8	28
29	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1939-1949.	4.2	27
30	Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis. <i>Oncolimmunology</i> , 2021, 10, 1877415.	4.6	32
31	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
32	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	2.4	20
33	Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e207911.	5.9	59
34	Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. , 2020, 8, e000537.		105
35	Conserved Interferon- $\gamma$ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	16.8	203
36	TERT amplification but not activation of canonical Wnt/ $\beta$ -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. <i>Modern Pathology</i> , 2020, 33, 2067-2074.	5.5	6

#	ARTICLE	IF	CITATIONS
37	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	1.6	23
38	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. <i>Nature Communications</i> , 2020, 11, 660.	12.8	68
39	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	12.8	124
40	Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. <i>Frontiers in Immunology</i> , 2020, 11, 590494.	4.8	21
41	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895.	7.0	42
42	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158
43	Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. <i>Blood</i> , 2020, 136, 1-1.	1.4	0
44	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. <i>Cancer</i> , 2019, 125, 4193-4202.	4.1	9
45	Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. , 2019, 7, 237.		88
46	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 553-561.	4.2	57
47	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
48	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R $\beta$ -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180
49	IL17A Blockade Successfully Treated Psoriasisiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865.	3.4	76
50	Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 <sup>+</sup> and CD16 <sup>+</sup> monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636.	1.3	27
51	THU0656...IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH CANCER AND RHEUMATOLOGIC DISEASES: A SYSTEMATIC REVIEW OF THE LITERATURE. , 2019, , .		0
52	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031.	3.7	23
53	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
54	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1903-1909.	3.4	86

#	ARTICLE	IF	CITATIONS
55	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	1.0	11
56	CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9601-TPS9601.	1.6	3
57	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	4.5	45
58	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193.	10.7	233
59	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
60	Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1695-1705.	1.9	177
61	Gut microbiome modulates response to anti-“PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
62	Metastatic Melanoma of the Optic Nerve Sheath. <i>Neuro-Ophthalmology</i> , 2018, 42, 187-190.	1.0	4
63	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
64	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
65	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-“PD1-Resistant Lung Tumor Model. <i>Clinical Cancer Research</i> , 2018, 24, 5735-5743.	7.0	48
66	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
67	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773.	1.3	38
68	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790.	1.3	18
69	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
70	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <i>Thyroid</i> , 2018, 28, 1243-1251.	4.5	160
71	NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3006-3006.	1.6	44
72	Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9510-9510.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Outcomes of metastatic melanoma (MM) patients (pts) after discontinuation of anti-Programmed-Death 1 (PD1) therapy without disease progression.. Journal of Clinical Oncology, 2018, 36, 9549-9549.	1.6	4
74	Checkpoint inhibitor induced glomerulonephritis.. Journal of Clinical Oncology, 2018, 36, e15083-e15083.	1.6	2
75	Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, TPS3133-TPS3133.	1.6	6
76	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patientsâ€™ Outcomes. Journal of Immunotherapy and Precision Oncology, 2018, 1, 7-18.	1.4	40
77	A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM).. Journal of Clinical Oncology, 2018, 36, TPS9598-TPS9598.	1.6	0
78	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research, 2017, 5, 100-105.	3.4	46
79	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689
80	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
81	Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the Rheumatic Diseases, 2017, 76, 2061-2064.	0.9	141
82	Erythema nodosumâ€”like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapyâ€”Report of 2 patients. Journal of Cutaneous Pathology, 2017, 44, 1080-1086.	1.3	48
83	Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nature Communications, 2017, 8, 1447.	12.8	67
84	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology, 2017, 44, 158-176.	1.3	186
85	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	7.0	261
86	FRIO604â€”Successful treatment of arthritis induced by checkpoint inhibitors with antiâ€”interleukin-6 receptor antibody: a case series. , 2017, , .		1
87	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohnâ€™s disease: a case report. Journal of Hematology and Oncology, 2016, 9, 81.	17.0	62
88	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitorâ€”Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	7.1	41
89	A case report of Groverâ€™s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
90	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785

#	ARTICLE	IF	CITATIONS
91	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolmunology</i> , 2016, 5, e1136044.	4.6	55
92	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
93	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838.	3.4	270
94	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0